Navigation tools for Image Guided Minimally invasive Therapies

Clinical Center

Investigators

Linked publications & trials

Abstract

Summary: Research in the Interventional Radiology (IR) lab is motivated by the fact that image guidance and minimally invasive approaches have revolutionized the management of many common diseases. However, diagnosis and therapy remain distinctly separated from each other in both time and space. We believe that this gap between diagnosis and therapy can be narrowed by minimally invasive image guided therapies and with the application of novel guidance technologies and engineered vectors. All research efforts in the IR lab are developed with a clear translational route to the clinic and address areas of urgent clinical need. The IR labs research program is separated into three main areas: 1. electromagnetic (EM) and optical tracking and robotics, 2. drug + device combinations, 3. novel methods or devices to improve or augment ablative energy delivery (RFA, MWA, Laser, IRE, or HIFU). The diversity of these projects requires an interdisciplinary team and takes full advantage of the interdisciplinary resources found within the Clinical Center and the Intramural Research Program. We believe that combining the imaging tools, with pharmaceuticals and medical devices can make a significant contribution to the future treatment of localized and systemic diseases, such as cancer. Principal projects are: 1) Smart biopsy, 2) OR of the future 3) Drugs + devices. Smart biopsy relies upon precise electromagnetic or gyroscopic tracking to target tissue to correlate sample with imaging parameters. OR of the future is a broad translational project that integrates a variety of technologies for navigation, automation, and visualization of medical procedures. Sub-projects within the Drug + Device model include: 1) Temperature sensitive liposomes combined with radiofrequency ablation (RFA) or high intensity focused ultrasound (HIFU), 2) Radiofrequency ablation or TACE combined with immunotherapy / checkpoint inhibitor therapy, and 3) Image-able drug eluting beads (DEB) for trans-catheter arterial chemoembolization (TACE). The clinical treatment of solid tumors could be improved by controlling the pharmacologic properties of anticancer therapeutics to deliver a greater dose to the tumor; with conventional drugs, this dose is typically limited by toxic systemic side effects in normal tissues. Therefore, the efficacy of current anticancer treatments may be improved with advances in drug delivery technologies and paradigms, augmented or delivered via needle or catheter. The goal of drug delivery in the treatment of cancer is to increase the concentration of a therapeutic agent in the tumor while limiting systemic exposure and subsequent normal tissue toxicity. The combination of drug delivery technologies with image guided interventions represents a rich field with great translational potential and the ability to bridge the gap between diagnosis and therapy. Diagnosis and therapy remain distinctly separated from each other in time and space. The gap between diagnosis and therapy can be closed by minimally invasive image guided therapies. Real-time, intra-procedural tools will blend diagnosis and therapy into a dynamic, iterative process with improved outcomes. The redefining of surgical-like procedures is fueled by multi-modality imaging, navigation, visualization, robotics, and automated precision tools. These enabling technologies have not yet been fully applied to existing clinical problems, especially in minimally-invasive image guided therapies. This presents an opportunity to integrate these technologies into the clinical setting in a validated and cost-effective manner, and to study the impact prior to broader implementation. Image guidance and multimodality navigation has fueled a small revolution in procedural medicine, which presents unprecedented opportunity and challenge. Image guidance and minimally invasive approaches have revolutionized the management of many common diseases. The miniaturization of surgical interventions has seen the broad adoption of needle or catheter-based procedures such as tumor embolization, brain aneurysm coiling, aortic stent grafting, uterine fibroid embolization, atherosclerosis stenting and angioplasty, and cancer thermal ablation or immune activation with radiofrequency or other energies. As procedures are becoming less and less invasive, they are more and more targeted and guided by imaging and spatial information. The ability to navigate a medical device to a target based upon multiple windows or multiple modalities should have tremendous advantages in certain settings. The combination of functional and morphologic (metabolic and anatomic) information on the same coordinate system is empowering to address questions such as the uncertainty of AI models for cancer diagnosis and classification or to decipher the temporal and spatial heterogeneities inherent to cancers. With multiple public and private partners, we have developed a multimodality interventional radiology suite that uses a CT coordinate frame to co-register and co-localize different devices including pre-procedural images, intra-procedural ultrasound, CT, rotational fluoroscopy, endoscopy, robotics, electromagnetic tracking and therapeutic ultrasound, microwave, radiofrequency, etc. to customize and characterize combinations of techniques and guidance methods tailored to address particular patient needs. Combining imaging modalities can take advantage of each modality's strength. Real-time feedback and temporal resolution of ultrasound can be combined with the functional and metabolic data from PET and the spatial resolution of MR or CT, all on one seamless platform for treatment planning, targeting, procedural navigation, monitoring, and verification of treatment. The lab has continued the electromagnetic tracking clinical trial with well over 2500 patients. The lab also further studied Medical GPS for tumor ablation and treatment planning and for prostate biopsies using MRI information without requiring an MRI to be physically present. A novel use of the smartphone gyroscope as a handheld approach to needle positioning has led to a cost effective application. Smartphone guidance has been added to a clinical trial and an augmented reality platform should be placed into clinical use this year. Partners have achieved European CE Mark approval for use of a related system in patients. This work yielded numerous discoveries, papers, and commercialized products. Also as a result of this work, numerous vendors in the field have adopted similar multi-modality approaches. Early Phase of laser ablation of prostate cancer under MRI guidance was completed and Phase II-III work began fall 2017 and has continued since for using ultrasound alone to guide the prostate cancer ablation. Low tech, cost-effective methods for navigation continued, including laser guidance for needle based biopsy and ablation, and bronchoscopy navigation and laser ablation development. Advanced work is in process for focal prostate therapies (transperineal access and transperineal ultrasound to get the whole system out of the rectum. Composite treatment planning was refined with several derivative clinical softwares soon commercially available. Drug eluting immuno-beads as a tool for regional therapies was refined in preclinical chemistry and is combined with image-able beads that show where the drug is being delivered in liver chemoembolization. Image-able drug eluting beads are being studied and refined in preclinical models and clinic, in order to develop drug dose planning software. Conductive catheters and endovascular devices for rapid artery occlusion were studied and prototyped, and NIH patents were issued on devices. Optical and EM needle endoscopy for biopsy will be tested under a UO1 grant and a clinical trial began in FY2021.